IL118069A - Monoclonal antibody reactive to human CETP and assay method for human CETP - Google Patents

Monoclonal antibody reactive to human CETP and assay method for human CETP

Info

Publication number
IL118069A
IL118069A IL11806996A IL11806996A IL118069A IL 118069 A IL118069 A IL 118069A IL 11806996 A IL11806996 A IL 11806996A IL 11806996 A IL11806996 A IL 11806996A IL 118069 A IL118069 A IL 118069A
Authority
IL
Israel
Prior art keywords
human cetp
monoclonal antibody
assay method
antibody reactive
cetp
Prior art date
Application number
IL11806996A
Other languages
English (en)
Other versions
IL118069A0 (en
Inventor
Masafumi Kamada
Hiroshi Okamoto
Takuya Tamatani
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of IL118069A0 publication Critical patent/IL118069A0/xx
Publication of IL118069A publication Critical patent/IL118069A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL11806996A 1995-05-02 1996-04-29 Monoclonal antibody reactive to human CETP and assay method for human CETP IL118069A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13483695 1995-05-02

Publications (2)

Publication Number Publication Date
IL118069A0 IL118069A0 (en) 1996-08-04
IL118069A true IL118069A (en) 2000-06-01

Family

ID=15137605

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11806996A IL118069A (en) 1995-05-02 1996-04-29 Monoclonal antibody reactive to human CETP and assay method for human CETP

Country Status (10)

Country Link
US (2) US6140474A (es)
EP (1) EP0825259B1 (es)
KR (1) KR100244573B1 (es)
AU (1) AU5515696A (es)
CA (1) CA2219947C (es)
DE (1) DE69635017T2 (es)
ES (1) ES2248808T3 (es)
IL (1) IL118069A (es)
IN (1) IN188167B (es)
WO (1) WO1996034948A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118069A (en) * 1995-05-02 2000-06-01 Japan Tobacco Inc Monoclonal antibody reactive to human CETP and assay method for human CETP
US20020028469A1 (en) * 1997-11-14 2002-03-07 Burch Ronald M. Method of defining genus of chemical compound and method of designing molecules
JP2000180442A (ja) * 1998-12-15 2000-06-30 Fuji Photo Film Co Ltd 血液濾過器
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
AT500648B1 (de) * 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie Set zur behandlung von krebspatienten
WO2009101092A1 (en) * 2008-02-13 2009-08-20 Novartis Ag Farp2 and stk25 and uses thereof
CN102791726B (zh) * 2010-03-10 2016-02-03 弗·哈夫曼-拉罗切有限公司 纯化免疫球蛋白溶液的方法
US10233502B2 (en) * 2011-06-22 2019-03-19 Indiana University Research And Technology Corporation Compositions for and methods of detecting, diagnosing, and prognosing thymic cancer
WO2013075040A1 (en) * 2011-11-16 2013-05-23 The Regents Of The University Of California Cholesterol ester transfer protein (cetp) inhibitor polypeptide antibodies for prophylactic and therapeutic anti-atherosclerosis treatments
BR112017006178A2 (pt) 2014-11-06 2018-05-02 F. Hoffmann-La Roche Ag região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
CN108588101B (zh) * 2018-04-27 2022-03-04 苏丹 构建同一基因不同表达载体的分子克隆方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5279540A (en) 1992-09-24 1994-01-18 Davidson Michael H Method for reducing the risk of atherosclerosis
JPH06169793A (ja) * 1992-12-02 1994-06-21 Eiken Chem Co Ltd モノクローナル抗体
JPH07128333A (ja) * 1993-11-09 1995-05-19 Nippon Koutai Kenkyusho:Kk コレステリルエステル転送蛋白の免疫測定法
IL118069A (en) * 1995-05-02 2000-06-01 Japan Tobacco Inc Monoclonal antibody reactive to human CETP and assay method for human CETP

Also Published As

Publication number Publication date
CA2219947A1 (en) 1996-11-07
DE69635017D1 (de) 2005-09-08
WO1996034948A1 (fr) 1996-11-07
EP0825259B1 (en) 2005-08-03
EP0825259A1 (en) 1998-02-25
CA2219947C (en) 2007-02-13
IL118069A0 (en) 1996-08-04
ES2248808T3 (es) 2006-03-16
KR19990008283A (ko) 1999-01-25
KR100244573B1 (ko) 2000-02-15
IN188167B (es) 2002-08-31
EP0825259A4 (en) 2001-04-25
AU5515696A (en) 1996-11-21
US6410020B1 (en) 2002-06-25
DE69635017T2 (de) 2006-06-01
US6140474A (en) 2000-10-31

Similar Documents

Publication Publication Date Title
EP0870826A4 (en) NEW PROTEINS AND MONOCLONAL ANTIBODIES AGAINST THESE
EP0759071A4 (en) MONOCLONAL ANTIBODIES AGAINST WT1 AND METHOD FOR THEIR USE
EP0921815A4 (en) THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
PL311926A1 (en) Anti-alphav-integrinic monoclonal antibodies
SG48420A1 (en) Humanized antibodies and uses thereof
EP0809806A4 (en) MONOCLONAL ANTIBODIES AGAINST SURFACE ANTIGENS OF OSTEOGENIC CELLS
IL118069A0 (en) Monoclonal antibody reactive to human cetp and assay method for human cetp
AU6220096A (en) Method for the simultaneous detection of different antibodies and/or antigens
AU3923293A (en) Human monoclonal antibodies and methods for human monoclonal antibody production
PL320610A1 (en) Fragments of monoclonal antibodies of immunosuppressive activity
AU5688596A (en) Anti-cd14 antibodies for use in the induction of il-10 secre tion
IL109232A0 (en) Human monoclonal antibodies and processes and materials for making such antibodies
AU7690496A (en) Monoclonal antiidiotypic antibodies (AB2) and their uses
IL102088A0 (en) Me20:monoclonal antibodies and antigen for human melanoma
AU9143991A (en) Monoclonal antibody op-g2 and method of use
AU6777594A (en) Human monoclonal antibodies to human cytomegalovirus, and methods therefor
ZA969164B (en) A method relating to the preparation of amorphous samples and means therefor
AU4910893A (en) Method for the simultaneous determination of antigens and antibodies
EP0407586A4 (en) Human monoclonal antibody and process for its preparation
EP1012605A4 (en) IMMUNOLOGICAL ANALYSIS PROCESS USING A MONOCLONAL ANTIBODY REACTING TO THE INNOVATIVE ENZYME OF HUMAN ORIGIN
GB9519460D0 (en) Polyclonal antibodies and their use
GB9506425D0 (en) New uses of monoclonal antibodies
AU715828C (en) Novel monoclonal antibody and method of immunological analysis of e-D-dimer and e-DD/E complex
IL110178A (en) Monoclonal antibodies specific to antigen-human MHC complex
GB9204514D0 (en) Monoclonal antibodies and their use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees